Skip to content
Back to meeting Original
OncLive.com路 @OncLive 路 X路路 2 hours agoScore70

KEYNOTE-C93

Body

馃幆 Median PFS of 38.2 vs 8.4 months: first-line pembrolizumab monotherapy beat carboplatin/paclitaxel in dMMR advanced or recurrent endometrial cancer in the phase 3 KEYNOTE-C93 trial (HR, 0.57). Full ESMO 2026 data 馃憞 #ESMO26 #gyncsm @myESMO @GynCancerMD @MountSinaiMiami https://hubs.li/Q04CmvxT0

64 views 路 0 likes 路 1 repost 路 0 replies

Source: OncLive.com 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.